Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$2 Mln
Revenue (TTM)
$-- Mln
Net Profit (TTM)
$-- Mln
ROE
-12.8 %
ROCE
-- %
P/E Ratio
0
P/B Ratio
0.5
Industry P/E
--
EV/EBITDA
1.2
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
565,500
CFO
$-44.27 Mln
EBITDA
$-46.71 Mln
Net Profit
$-43.52 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Scisparc (SPRC)
| -70.8 | -28.5 | -70.8 | -93.3 | -88.3 | -- | -- |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
|---|---|---|
|
Scisparc (SPRC)
| -82.0 | -75.2 |
|
S&P Small-Cap 600
| 4.0 | 13.9 |
|
BSE Sensex
| 9.1 | 18.7 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Scisparc (SPRC)
|
3.6 | 2.0 | 1.3 | -6.3 | -- | -79.7 | 0 | 0.5 |
| 8.5 | 466.6 | 195.3 | 21.9 | 12.7 | 8.3 | 23.1 | 1.8 | |
| 16.8 | 198.6 | 17.0 | -23.9 | -96.8 | -63.9 | -- | 4.5 | |
| 2.1 | 1.9 | 0.0 | -4.8 | -- | -93.3 | 0 | 0.2 | |
| 4.4 | 80.3 | 0.0 | -34.2 | -- | -366.3 | -- | 7.2 |
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the... treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially manufacture SCI-110, palmitoylethanolamide oral tablets and CannAmide in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel. Address: Tower A, Tel Aviv-Yafo, Israel, 6971916 Read more
CEO & CFO
Mr. Oz Adler CPA
President & Director
Mr. Itschak Shrem
Headquarters
Tel Aviv-Yafo
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Scisparc Ltd (SPRC) is $3.57 (NASDAQ) as of 02-Apr-2026 16:00 EDT. Scisparc Ltd (SPRC) has given a return of -88.27% in the last 3 years.
Since, TTM earnings of Scisparc Ltd (SPRC) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
The 52-week high and low of Scisparc Ltd (SPRC) are Rs 94.50 and Rs 3.37 as of 04-Apr-2026.
Scisparc Ltd (SPRC) has a market capitalisation of $ 2 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Scisparc Ltd (SPRC), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.09
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.